New drug shows promise in destroying amyloidosis cells

NCT ID NCT07524634

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called elranatamab in people newly diagnosed with AL amyloidosis who have not yet had treatment. The drug helps the body's immune cells find and destroy the abnormal cells causing the disease. Researchers want to see if it can produce deep remissions and improve organ function, and they are comparing two different dosing schedules. About 64 participants will receive injections over 6 months and be followed for up to 2 years.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYLOID LIGHT-CHAIN AMYLOIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AL amyloidosis Immunoglobulin Light-chain Amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute

    Cleveland, Ohio, 44195, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Mayo Clinic

    Rochester, Minnesota, 55902, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact